Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed…
Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher response rates observed with these agents have led to their integration into induction therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent advances in the management of plasmacytomas, renal dysfunction, dentistry as well as mobilization of stem cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt has been to present before the reader a comprehensive yet brief text on this important subject.
Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher response rates observed with these agents have led to their integration into induction therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent advances in the management of plasmacytomas, renal dysfunction, dentistry as well as mobilization of stem cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt has been to present before the reader a comprehensive yet brief text on this important subject.
Atsiliepimai
Atsiliepimų nėra
0 pirkėjai įvertino šią prekę.
5
0%
4
0%
3
0%
2
0%
1
0%
Kainos garantija
Ženkliuku „Kainos garantija” pažymėtoms prekėms Knygos.lt garantuoja geriausią kainą. Jei identiška prekė kitoje internetinėje parduotuvėje kainuoja mažiau - kompensuojame kainų skirtumą. Kainos lyginamos su knygos.lt nurodytų parduotuvių sąrašu prekių kainomis. Knygos.lt įsipareigoja kompensuoti kainų skirtumą pirkėjui, kuris kreipėsi „Kainos garantijos” taisyklėse nurodytomis sąlygomis. Sužinoti daugiau
Elektroninė knyga
22,39 €
DĖMESIO!
Ši knyga pateikiama ACSM formatu. Jis nėra tinkamas įprastoms skaityklėms, kurios palaiko EPUB ar MOBI formato el. knygas.
Svarbu! Nėra galimybės siųstis el. knygų jungiantis iš Jungtinės Karalystės.
Tai knyga, kurią parduoda privatus žmogus. Kai apmokėsite užsakymą, jį per 7 d. išsiųs knygos pardavėjas . Jei to pardavėjas nepadarys laiku, pinigai jums bus grąžinti automatiškai.
Šios knygos būklė nėra įvertinta knygos.lt ekspertų, todėl visa atsakomybė už nurodytą knygos kokybę priklauso pardavėjui.
Atsiliepimai